Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Breast Cancer
•
Radiation Oncology
Is it reasonable to use hypofractionation in breast cancer patients with non-active connective tissue disorders?
Answer from: Radiation Oncologist at Academic Institution
Yes, it is reasonable to use hypofractionation in this patient panel. I have used the Canadian fractionation schedule several times in this scenario.
Sign in or Register to read more
Answer from: Radiation Oncologist at Community Practice
I’ve also routinely done this with no issue at all.
Sign in or Register to read more
15771
15793
Related Questions
What is your approach to women with breast cancer who opts for a staged approach with up-front lumpectomy and SLN biopsy (pN-) when there are indications for adjuvant radiation therapy but she plans for a later mastectomy (=>6 months)?
Is it appropriate to use bolus with hypofractionated PMRT?
How would you approach surveillance imaging for men with early-stage, hormone receptor-positive breast cancer after unilateral mastectomy?
When treating chestwall + RNI with VMAT, how much do you crop the PTV into lung as is done with the PTVeval in 3D contouring guides?
Would you offer ultra-hypofractionated accelerated partial breast re-irradiation using 5 fractions?
Is there any increased risk with adjuvant breast radiation for a patient with muscular dystrophy?
Do you recommend adjuvant RT to patients with non-ATM genetic mutations (e.g. BRCA, NF) who elect to have lumpectomy and are otherwise PRIME II/CALGB candidates for RT omission (i.e. low risk disease characteristics: strongly ER+, <1cm, grade 1-2, no LVI, widely negative margins, and committed to endocrine therapy)?
When using surface image-guidance for breast radiation, how do you accommodate for changes in anatomy?
Would you offer ultrahypofractionated 5-fraction whole breast only for a women with ER-/HER2+/cN+ disease with pCR following neoadjuvant systemic therapy?
Given the final publication of NSABP B-51, for which patients meeting trial eligibility would you still recommend regional nodal irradiation?